BRENDA - Enzyme Database show
show all sequences of 1.14.14.55

The in vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes

Zhao, X.J.; Ishizaki, T.; J. Pharmacol. Exp. Ther. 283, 1168-1176 (1997)

Data extracted from this reference:

Activating Compound
Activating Compound
Commentary
Organism
Structure
alpha-naphthoflavone
-
Canis lupus familiaris
alpha-naphthoflavone
-
Homo sapiens
diazepam
-
Canis lupus familiaris
diazepam
-
Homo sapiens
Inhibitors
Inhibitors
Commentary
Organism
Structure
alpha-naphthoflavone
-
Mus musculus
alpha-naphthoflavone
-
Rattus norvegicus
anti-CYP3A4 antibodies
inhibition of 92%
Canis lupus familiaris
anti-CYP3A4 antibodies
-
Homo sapiens
anti-CYP3A4 antibodies
inhibition of 96%
Mus musculus
anti-CYP3A4 antibodies
inhibition of 84%
Rattus norvegicus
Chloroquin
-
Canis lupus familiaris
Chloroquin
-
Rattus norvegicus
diazepam
-
Mus musculus
diazepam
-
Rattus norvegicus
doxycyclin
-
Canis lupus familiaris
doxycyclin
-
Homo sapiens
doxycyclin
-
Rattus norvegicus
ketoconazole
maximum inhibition of 88%
Canis lupus familiaris
ketoconazole
maximum inhibition of 90%
Homo sapiens
ketoconazole
maximum inhibition of 94%
Mus musculus
ketoconazole
maximum inhibition of 91%
Rattus norvegicus
p-nitrophenol
inhibition observed but not quantified
Homo sapiens
p-nitrophenol
inhibits more than 75% at 10 mM
Mus musculus
primaquine
-
Canis lupus familiaris
primaquine
-
Rattus norvegicus
primaquine
-
Homo sapiens
S-mephenytoin
-
Homo sapiens
S-mephenytoin
inhibits more than 70% at 0.5 mM
Mus musculus
sulfaphenazole
inhibits more than 50% at 0.1 mM
Mus musculus
tetracyclin
-
Canis lupus familiaris
tetracyclin
-
Homo sapiens
tetracyclin
-
Rattus norvegicus
troleandomycin
maximum inhibition of 93%
Canis lupus familiaris
troleandomycin
maximum inhibition of 70%
Homo sapiens
troleandomycin
maximum inhibition of 85%
Mus musculus
troleandomycin
maximum inhibition of 66%
Rattus norvegicus
KM Value [mM]
KM Value [mM]
KM Value Maximum [mM]
Substrate
Commentary
Organism
Structure
0.0227
-
Quinine
-
Rattus norvegicus
0.0297
-
Quinine
-
Mus musculus
0.105
-
Quinine
-
Homo sapiens
0.138
-
Quinine
-
Canis lupus familiaris
Localization
Localization
Commentary
Organism
GeneOntology No.
Textmining
microsome
-
Canis lupus familiaris
-
-
microsome
-
Mus musculus
-
-
microsome
-
Rattus norvegicus
-
-
microsome
-
Homo sapiens
-
-
Organism
Organism
Primary Accession No. (UniProt)
Commentary
Textmining
Canis lupus familiaris
-
dog
-
Homo sapiens
-
human
-
Mus musculus
-
mouse
-
Rattus norvegicus
-
rat
-
Source Tissue
Source Tissue
Commentary
Organism
Textmining
liver
-
Canis lupus familiaris
-
liver
-
Mus musculus
-
liver
-
Rattus norvegicus
-
liver
-
Homo sapiens
-
Substrates and Products (Substrate)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
quinine + NADPH + O2
-
285329
Mus musculus
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
quinine + NADPH + O2
-
285329
Homo sapiens
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
quinine + NADPH + O2
-
285329
Rattus norvegicus
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
quinine + NADPH + O2
-
285329
Canis lupus familiaris
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
Activating Compound (protein specific)
Activating Compound
Commentary
Organism
Structure
alpha-naphthoflavone
-
Canis lupus familiaris
alpha-naphthoflavone
-
Homo sapiens
diazepam
-
Canis lupus familiaris
diazepam
-
Homo sapiens
Inhibitors (protein specific)
Inhibitors
Commentary
Organism
Structure
alpha-naphthoflavone
-
Mus musculus
alpha-naphthoflavone
-
Rattus norvegicus
anti-CYP3A4 antibodies
inhibition of 92%
Canis lupus familiaris
anti-CYP3A4 antibodies
-
Homo sapiens
anti-CYP3A4 antibodies
inhibition of 96%
Mus musculus
anti-CYP3A4 antibodies
inhibition of 84%
Rattus norvegicus
Chloroquin
-
Canis lupus familiaris
Chloroquin
-
Rattus norvegicus
diazepam
-
Mus musculus
diazepam
-
Rattus norvegicus
doxycyclin
-
Canis lupus familiaris
doxycyclin
-
Homo sapiens
doxycyclin
-
Rattus norvegicus
ketoconazole
maximum inhibition of 88%
Canis lupus familiaris
ketoconazole
maximum inhibition of 90%
Homo sapiens
ketoconazole
maximum inhibition of 94%
Mus musculus
ketoconazole
maximum inhibition of 91%
Rattus norvegicus
p-nitrophenol
inhibition observed but not quantified
Homo sapiens
p-nitrophenol
inhibits more than 75% at 10 mM
Mus musculus
primaquine
-
Canis lupus familiaris
primaquine
-
Rattus norvegicus
primaquine
-
Homo sapiens
S-mephenytoin
-
Homo sapiens
S-mephenytoin
inhibits more than 70% at 0.5 mM
Mus musculus
sulfaphenazole
inhibits more than 50% at 0.1 mM
Mus musculus
tetracyclin
-
Canis lupus familiaris
tetracyclin
-
Homo sapiens
tetracyclin
-
Rattus norvegicus
troleandomycin
maximum inhibition of 93%
Canis lupus familiaris
troleandomycin
maximum inhibition of 70%
Homo sapiens
troleandomycin
maximum inhibition of 85%
Mus musculus
troleandomycin
maximum inhibition of 66%
Rattus norvegicus
KM Value [mM] (protein specific)
KM Value [mM]
KM Value Maximum [mM]
Substrate
Commentary
Organism
Structure
0.0227
-
Quinine
-
Rattus norvegicus
0.0297
-
Quinine
-
Mus musculus
0.105
-
Quinine
-
Homo sapiens
0.138
-
Quinine
-
Canis lupus familiaris
Localization (protein specific)
Localization
Commentary
Organism
GeneOntology No.
Textmining
microsome
-
Canis lupus familiaris
-
-
microsome
-
Mus musculus
-
-
microsome
-
Rattus norvegicus
-
-
microsome
-
Homo sapiens
-
-
Source Tissue (protein specific)
Source Tissue
Commentary
Organism
Textmining
liver
-
Canis lupus familiaris
-
liver
-
Mus musculus
-
liver
-
Rattus norvegicus
-
liver
-
Homo sapiens
-
Substrates and Products (Substrate) (protein specific)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
quinine + NADPH + O2
-
285329
Mus musculus
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
quinine + NADPH + O2
-
285329
Homo sapiens
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
quinine + NADPH + O2
-
285329
Rattus norvegicus
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
quinine + NADPH + O2
-
285329
Canis lupus familiaris
3-hydroxyquinine + NADP+ + H2O
-
-
-
?
Other publictions for EC 1.14.14.55
No.
1st author
Pub Med
title
organims
journal
volume
pages
year
Activating Compound
Application
Cloned(Commentary)
Crystallization (Commentary)
Engineering
General Stability
Inhibitors
KM Value [mM]
Localization
Metals/Ions
Molecular Weight [Da]
Natural Substrates/ Products (Substrates)
Organic Solvent Stability
Organism
Oxidation Stability
Posttranslational Modification
Purification (Commentary)
Reaction
Renatured (Commentary)
Source Tissue
Specific Activity [micromol/min/mg]
Storage Stability
Substrates and Products (Substrate)
Subunits
Temperature Optimum [°C]
Temperature Range [°C]
Temperature Stability [°C]
Turnover Number [1/s]
pH Optimum
pH Range
pH Stability
Cofactor
Ki Value [mM]
pI Value
IC50 Value
Activating Compound (protein specific)
Application (protein specific)
Cloned(Commentary) (protein specific)
Cofactor (protein specific)
Crystallization (Commentary) (protein specific)
Engineering (protein specific)
General Stability (protein specific)
IC50 Value (protein specific)
Inhibitors (protein specific)
Ki Value [mM] (protein specific)
KM Value [mM] (protein specific)
Localization (protein specific)
Metals/Ions (protein specific)
Molecular Weight [Da] (protein specific)
Natural Substrates/ Products (Substrates) (protein specific)
Organic Solvent Stability (protein specific)
Oxidation Stability (protein specific)
Posttranslational Modification (protein specific)
Purification (Commentary) (protein specific)
Renatured (Commentary) (protein specific)
Source Tissue (protein specific)
Specific Activity [micromol/min/mg] (protein specific)
Storage Stability (protein specific)
Substrates and Products (Substrate) (protein specific)
Subunits (protein specific)
Temperature Optimum [°C] (protein specific)
Temperature Range [°C] (protein specific)
Temperature Stability [°C] (protein specific)
Turnover Number [1/s] (protein specific)
pH Optimum (protein specific)
pH Range (protein specific)
pH Stability (protein specific)
pI Value (protein specific)
Expression
General Information
General Information (protein specific)
Expression (protein specific)
KCat/KM [mM/s]
KCat/KM [mM/s] (protein specific)
745448
Igbinoba
Influence of a Nigerian honey ...
Homo sapiens
J. Clin. Pharm. Ther.
40
545-549
2015
-
-
-
-
-
-
1
-
-
-
-
1
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
703423
Wanwimolruk
Variable inhibitory effect of ...
Homo sapiens
Drug Metabol. Drug Interact.
24
17-35
2009
1
1
-
-
-
-
3
-
1
-
-
-
-
6
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
1
1
-
1
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
706089
Diczfalusy
4Beta-hydroxycholesterol is a ...
Homo sapiens
Pharmacogenet. Genomics
18
201-208
2008
-
1
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
686501
Allqvist
Inhibition of CYP3A4 and CYP3A ...
Homo sapiens
Eur. J. Clin. Pharmacol.
63
173-179
2007
-
-
-
-
-
-
5
1
1
-
-
1
-
2
-
-
1
-
-
1
-
-
1
-
1
-
-
-
1
-
-
1
-
-
5
-
-
-
1
-
-
-
5
5
-
1
1
-
-
1
-
-
-
1
-
1
-
-
1
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
676312
Mirghani
CYP3A5 genotype has significan ...
Homo sapiens
Pharmacogenet. Genomics
16
637-645
2006
-
-
1
-
2
-
-
-
-
-
-
1
-
1
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
1
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744749
Numata
Ontogeny of hepatic microsoma ...
Pygoscelis adeliae
Comp. Biochem. Physiol. C
138
53-58
2004
-
-
-
-
-
-
3
-
1
-
-
1
-
3
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
1
-
-
1
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744838
Mirghani
Quinine 3-hydroxylation as a ...
Homo sapiens
Eur. J. Clin. Pharmacol.
59
23-28
2003
-
-
-
-
-
-
1
-
-
-
-
1
-
2
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744611
Wanwimolruk
Is quinine a suitable probe t ...
Homo sapiens
Br. J. Clin. Pharmacol.
54
643-651
2002
-
-
-
-
-
-
1
-
-
-
-
1
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744769
Mirghani
Enzyme kinetics for the forma ...
Homo sapiens
Drug Metab. Dispos.
30
1368-1371
2002
-
-
-
-
-
-
3
-
1
-
-
1
-
2
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
1
-
-
1
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744743
Mirghani
The roles of cytochrome P450 ...
Homo sapiens
Clin. Pharmacol. Ther.
66
454-460
1999
-
-
-
-
-
-
2
-
-
-
-
1
-
1
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
1
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
285328
Zhao
Mutual inhibition between quin ...
Homo sapiens
Drug Metab. Dispos.
26
188-191
1997
-
-
-
-
-
-
4
-
1
-
-
-
-
2
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
1
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
285329
Zhao
The in vitro hepatic metabolis ...
Canis lupus familiaris, Homo sapiens, Mus musculus, Rattus norvegicus
J. Pharmacol. Exp. Ther.
283
1168-1176
1997
4
-
-
-
-
-
32
4
4
-
-
-
-
10
-
-
-
-
-
4
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
-
-
32
-
4
4
-
-
-
-
-
-
-
-
4
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744608
Zhang
Evidence for involvement of h ...
Homo sapiens
Br. J. Clin. Pharmacol.
43
245-252
1997
1
-
-
-
-
-
4
1
1
-
-
1
-
2
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
4
1
1
1
-
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744609
Zhao
Metabolic interactions of sel ...
Homo sapiens
Br. J. Clin. Pharmacol.
44
505-511
1997
1
-
-
-
-
-
14
-
1
-
-
1
-
1
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
13
1
-
-
-
-
-
-
13
14
-
-
1
-
-
1
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
285327
Zhao
Identification of human cytoch ...
Homo sapiens
J. Pharmacol. Exp. Ther.
279
1327-1334
1996
-
-
1
-
-
-
5
3
1
-
-
-
-
2
-
-
-
-
-
1
-
-
1
-
-
-
-
2
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
5
-
3
1
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
285330
Relling
Human cytochrome P450 metaboli ...
Homo sapiens
J. Pharmacol. Exp. Ther.
261
491-496
1992
-
-
-
-
-
-
-
2
1
-
-
-
-
1
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
1
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-